WE KEEP RUNNING INTO THIS PROBLEM: NIH superbug outbreak highlights lack of new antibiotics. “Experts point to three reasons pharmaceutical companies have pulled back from antibiotics despite two decades of screaming alarms from the public health community: There is not much money in it; inventing new antibiotics is technically challenging; and, in light of drug safety concerns, the FDA has made it difficult for companies to get new antibiotics approved.”

But the story spins it as a failure of capitalism. Excuse me?